Hospital
Mercy Medical Center of Oshkosh, INC.
Mercy Medical Center of Oshkosh, INC. was paid $486K by Medicaid between Jan 2018 and Dec 2021, across 121 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoMERCY MEDICAL CENTER OF OSHKOSH, INC.
OSHKOSH, WI 54904
OSHKOSH, WI 54904
33aNPI1023065356assigned 05/30/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$486K
24GClaims20,805
24DCodes billed121
24AFirst – last monthJan 2018 – Dec 2021
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#46 of 60
Median peer was paid$2.90M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCCULLOUGH, MICHAEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,767 | $486K | |
| 2021 | 38 | $0.00 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 751 | 687 | $50K |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.8% | 427 | 316 | $48K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.9% | 697 | 614 | $38K |
| 80053 | Comprehensive metabolic panel | 7.8% | 1,126 | 926 | $38K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 5.4% | 246 | 225 | $26K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.2% | 571 | 483 | $20K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.7% | 590 | 516 | $18K |
| G0378 | Hospital observation service, per hour | 3.6% | 221 | 157 | $18K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 3.0% | 167 | 115 | $15K |
| 87631 | 3.0% | 108 | 99 | $14K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.5% | 570 | 474 | $12K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.1% | 99 | 91 | $10K |
109 more codes
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.0% | 211 | $10K |
| G0306 | Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count | 1.9% | 673 | $9K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 114 | $9K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.8% | 191 | $9K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 143 | $8K |
| 80061 | Lipid panel | 1.4% | 431 | $7K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.3% | 196 | $6K |
| 80306 | 1.3% | 265 | $6K | |
| 81001 | 1.2% | 780 | $6K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 121 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.2% | 128 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 268 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 115 | $4K |
| 85610 | <1% | 368 | $4K | |
| 82950 | <1% | 74 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 75 | $3K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 21 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 493 | $3K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 75 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 56 | $2K |
| 82947 | <1% | 183 | $2K | |
| 84702 | <1% | 44 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 25 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 65 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 214 | $2K |
| 86850 | <1% | 145 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 245 | $2K |
| 81025 | <1% | 152 | $2K | |
| 84703 | <1% | 193 | $2K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 65 | $2K |
| 83690 | <1% | 229 | $2K | |
| 84484 | <1% | 216 | $2K | |
| 87653 | <1% | 38 | $2K | |
| 82607 | <1% | 95 | $2K | |
| G0307 | Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) | <1% | 175 | $2K |
| 82565 | <1% | 83 | $2K | |
| 86803 | <1% | 68 | $1K | |
| 87340 | <1% | 118 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 58 | $1K |
| 86780 | <1% | 114 | $1K | |
| 82728 | <1% | 77 | $1K | |
| 86140 | <1% | 133 | $1K | |
| 86762 | <1% | 64 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 87 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 27 | $1K |
| 87081 | <1% | 28 | $1K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $1K |
| 87070 | <1% | 119 | $1K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $1K |
| 86900 | <1% | 157 | $1K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 98 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 163 | $1K |
| 83735 | <1% | 158 | $1K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 415 | $1K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 21 | $930.69 |
| 87205 | <1% | 116 | $864.00 | |
| 84439 | <1% | 86 | $804.51 | |
| 85379 | <1% | 90 | $707.49 | |
| 87186 | <1% | 76 | $660.63 | |
| 84460 | <1% | 100 | $608.18 | |
| 84153 | <1% | 12 | $591.62 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 75 | $566.98 |
| 82043 | <1% | 46 | $560.57 | |
| 83655 | <1% | 33 | $557.03 | |
| 86787 | <1% | 80 | $556.50 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $479.63 |
| 86901 | <1% | 160 | $476.55 | |
| 80076 | <1% | 56 | $461.19 | |
| 85027 | <1% | 116 | $433.04 | |
| 85730 | <1% | 93 | $382.51 | |
| 74018 | <1% | 54 | $373.75 | |
| 83550 | <1% | 25 | $266.81 | |
| 84450 | <1% | 48 | $264.70 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 47 | $236.42 |
| 83605 | <1% | 35 | $224.73 | |
| 83540 | <1% | 27 | $216.51 | |
| 87040 | <1% | 13 | $178.66 | |
| 86038 | <1% | 12 | $178.16 | |
| 85018 | <1% | 64 | $174.41 | |
| 71045 | Radiologic examination, chest; single view | <1% | 228 | $167.28 |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,642 | $160.82 |
| 87077 | <1% | 14 | $100.50 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 48 | $83.67 |
| 85652 | <1% | 35 | $65.49 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 17 | $33.03 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 458 | $27.47 |
| 73630 | <1% | 12 | $17.28 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 280 | $11.11 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 256 | $6.58 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 296 | $4.71 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 146 | $3.03 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 43 | $1.24 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 206 | $0.81 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 166 | $0.78 |
| 88312 | 0% | 15 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 126 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 20 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 357 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 197 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 27 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 12 | $0.00 |
| J1094 | Injection, dexamethasone acetate, 1 mg | 0% | 60 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 60 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 32 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 18 | $0.00 |
| 94644 | 0% | 13 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 41 | $0.00 |
| 80320 | 0% | 15 | $0.00 | |
| 96376 | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCULLOUGH, MICHAEL (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.